What about Wuhan Hualong biopharmaceutical co., ltd?

Introduction: Wuhan Hualong biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise and a wholly-owned subsidiary of Guangxin Group. Mainly engaged in research and development, production and sales of high-tech biopharmaceuticals such as biopharmaceuticals, biochemical drugs and genetically engineered drugs.

The company is located in Hualong Biotechnology Park, Zoumaling Sub-district Office, Dongxihu District, Wuhan. The total area is 69,907 square meters, and the building area of the workshop is nearly 30,000 square meters. In June 5438+February, 2000, the company basically passed the GMP certification of the State Food and Drug Administration, and in June 5438+1October, 2009, it passed the GMP five-year renewal inspection of the State Food and Drug Administration again. There are 62 kinds of products with different specifications. In February, 2008, it was jointly evaluated as a "high-tech enterprise" by Hubei Science and Technology Department, Finance Department, State Taxation Bureau and Local Taxation Bureau.

After more than ten years of development, the company's production conditions are becoming more and more perfect, and there are four production lines, including: the annual production capacity of freeze-dried powder injection (penicillin bottle)150 thousand; The annual production capacity of small-volume injections is 20 million; The annual production capacity of large-capacity injections (glass bottles) is 5 million bottles; The annual production capacity of large-capacity injections (polypropylene bottles) is 5 million bottles.

The company has 230 employees, including 5 masters, 3 1 person with intermediate title, 5 licensed pharmacists and nearly 0/00 college graduates. Since its establishment, the company has developed 45 new products (including product specifications) and obtained 35 new drug production approvals. Polygelatin peptide injection is a patented product independently developed by our company, which is a national torch plan project. The company has established a research and development platform for polypeptide drugs, and cooperated with many domestic universities to develop new drugs with independent intellectual property rights.

Factory Address: Xinhua Jihualong Biotechnology Park, Zoumaling Street, Dongxihu District, Wuhan

Marketing address: Room 2008, Block C, Hongrun Building, Derun Building, Jiang 'an District, Wuhan

Recruitment email: wuhanhualong@ 126.com

Legal Representative: Lu.

Date of establishment: 2000- 10- 10

Registered capital: 40 million yuan.

Region: Hubei Province

Unified social credit code: 91420100724663678x.

Business status: surviving (in business, in business, on record)

Industry: manufacturing industry

Company type: limited liability company (Taiwan, Hong Kong and Macao joint venture)

English name: Wuhan Hualong biopharmaceutical co., ltd.

Number of employees: 100-499.

Enterprise address: No.31Wuhuan Avenue, Dongxihu District, Wuhan

Business scope: production and sales of freeze-dried powder injection, large-capacity injection (glass infusion bottle, polypropylene infusion bottle 1 line), small-capacity injection and raw material medicine (ganciclovir); And the import and export trade of the above commodities (excluding the distribution business of imported commodities). (Projects subject to approval according to law can only be operated after approval by relevant departments)